Although targeting IL-1β or ICAM1 is a promising concept, there are no clinical trials that have assessed targeting IL-1β or ICAM1 for HNSCC treatment, and more research in this area is warranted. Here, IL1B is linked to head and neck squamous cell carcinoma.